EGFR and lung carcinoma: In an EGFR-TKIs-resistant lung cancer mouse model, the HH inhibitor, LDE225 (Sonidegib), in combination with gefitinib significantly inhibited tumor growth than gefitinib alone, completely inhibiting the phosphorylation of PI3K/AKT and MAPK signaling.